BACH2 and systemic lupus erythematosus: Furthermore, CD28 has been predicted as a primary drug target for AIT based on three considerations: its expression can be influenced by the cis-acting signal of BACH2 underlying coincident associations; its pharmacological modulation might reproduce a therapeutic protective effect on AIT; and the anti-CD28 drug was already developed for SLE (24).